ArticlePulmonary circulation
Levosimendan in pulmonary hypertension and right heart failure.
Article in Pulmonary circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Levosimendan Administration in High Risk Cardiac Surgery Patients With Pulmonary Hypertension
Comparison of Intravenous Levosimendan and Inhalational Milrinone in High Risk Cardiac Patients With Pulmonary Hypertension
Who cites it
34 citing papers in PubMed, 72 citations in OpenAlex.
- The Right Ventricle in Cardiac Critical Care: Pathophysiology, Evaluation and Management.Medicina (Kaunas, Lithuania) · 2026Review
- The potential effect of calcium sensitizer in pulmonary hypertension post-coronavirus disease-19 infection in presumptive familial dilated cardiomyopathy: a case report.Journal of medical case reports · 2026Article
- Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.Journal of aerosol medicine and pulmonary drug delivery · 2024Review
- Intravenous Levosimendan versus Inhalational Milrinone in the Management of Pulmonary Hypertension during Adult Cardiac Surgery: A Randomized Clinical Trial.Life (Basel, Switzerland) · 2024Article
- Review
- Levosimendan mediates the BMP/Smad axis through upregulation of circUSP34-targeted miR-1298 to alleviate pulmonary hypertension.Respiratory research · 2024Article
- Medical and Mechanical Circulatory Support of the Failing Right Ventricle.Current cardiology reports · 2024Review
- Editorial: Right ventricular failure: current strategies and future development.Frontiers in cardiovascular medicine · 2024Article
- Evaluation of levosimendan as treatment option in a large case-series of preterm infants with cardiac dysfunction and pulmonary hypertension.European journal of pediatrics · 2023Article
- Monitoring of Levosimendan Administration in Patients with Pulmonary Hypertension Undergoing Cardiac Surgery and Effect of Two Different Dosing Schemes on Hemodynamic and Echocardiographic Parameters.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Right ventricular failure: Current strategies and future development.Frontiers in cardiovascular medicine · 2023Review
- Fluid management in septic patients with pulmonary hypertension, review of the literature.Frontiers in cardiovascular medicine · 2023Review
- Use of Levosimendan in Patients with Advanced Heart Failure: An Update.Journal of clinical medicine · 2022Review
- An updated meta-analysis of hemodynamics markers of prognosis in patients with pulmonary hypertension due to left heart disease.Pulmonary circulation · 2022Article
- The right ventricular involvement in dilated cardiomyopathy: prevalence and prognostic implications of the often-neglected child.Heart failure reviews · 2022Review
- Levosimendan in intensive care and emergency medicine: literature update and expert recommendations for optimal efficacy and safety.Journal of anesthesia, analgesia and critical care · 2022Review
- Cardiopulmonary disease as sequelae of long-term COVID-19: Current perspectives and challenges.Frontiers in medicine · 2022Review
- Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.Frontiers in medicine · 2022Article
- Perioperative approach to precapillary pulmonary hypertension in non-cardiac non-obstetric surgery.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Levosimendan-induced venodilation is mediated by opening of potassium channels.ESC heart failure · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension is a multifactorial disease with a high morbidity and mortality. Right ventricular function is the most important predictor of morbidity and mortality in patients suffering from pulmonary hypertension, but currently there are no approved treatments directly supporting the failing right ventricle. Levosimendan is a calcium sensitizing agent with inotropic, pulmonary vasodilatory, and cardioprotective properties. Given its pharmacodynamic profile, levosimendan could be a potential novel agent for the treatment of right ventricular failure caused by pulmonary hypertension. The aim of this review is to provide an overview of the current knowledge on the effects of levosimendan in pulmonary hypertension and right heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.